ABBV vs CRWD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and CrowdStrike Holdings, Inc. โ fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. ยท Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
CrowdStrike Holdings, Inc. ยท Technology
$259.67
-13.1% upside to fair value
Low Conviction
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs โ not personalized investment advice.
See all research โ
Valuation & Fundamentals
| Metric |
ABBV |
CRWD |
| Current Price |
$261.70 |
$259.67 |
| Fair Value Estimate |
$259.04 |
$225.56 |
| Upside to Fair Value |
-1.0%
|
-13.1%
|
| Market Cap |
$462.4B |
$264.4B |
| Forward P/E |
โ
|
โ
|
| EV / EBITDA |
24.8x
|
595.7x
|
| Price / Sales |
7.2x
|
49.0x
|
| Price / FCF |
23.6x
|
167.9x
|
| Revenue Growth YoY |
+10.2%
|
+25.8%
|
| Gross Margin |
71.5%
|
75.2%
|
| Operating Margin |
29.3%
|
-2.2%
|
| Return on Equity |
-136.5%
|
1.3%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
0.6%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset aโฆ
CrowdStrike Holdings is a cloud-native cybersecurity platform company that sells subscriptions to its Falcon platform and a growing array of cloud modules spanning endpoint protection, cloud workload security, identity protection, Next-Gen SIEM, threat intelligence, and managed services, generating revenue through a direct sales force and channel partners from its Austin, Texas headquarters with โฆ
Accumulation Zones
| Metric |
ABBV |
CRWD |
| Zone Low |
$194.28 |
$169.17 |
| Zone High |
$220.18 |
$191.73 |
| In Buy Zone? |
No
|
No
|